Axonics Inc
NASDAQ:AXNX
Operating Margin
Axonics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Axonics Inc
NASDAQ:AXNX
|
3.6B USD |
-2%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
215.2B USD |
18%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
185.9B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
153.3B USD |
19%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
148.8B USD |
22%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
114.9B USD |
20%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
51.7B EUR |
14%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
51.3B USD |
13%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45B USD |
28%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
41.5B USD |
29%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
273.2B CNY |
34%
|
Axonics Inc
Glance View
Axonics Inc., a prominent player in the medical technology landscape, has carved a niche for itself by focusing diligently on the development and commercialization of innovative solutions for bladder and bowel dysfunction. Founded in 2012, the company's primary product is its Sacral Neuromodulation (SNM) system, designed to treat urinary and fecal incontinence. What differentiates Axonics is its dedication to addressing a pervasive issue with an underpinning focus on patient-centric design and effective long-term treatment. Its SNM system offers users rechargeable batteries, providing a less invasive and more cost-effective solution compared to traditional systems. This technology not only addresses significant medical needs but also aligns well with a growing trend toward minimally invasive solutions in medtech. The operational model of Axonics is straightforward yet well-suited to drive profitability. Revenues primarily derive from the sales of its SNM system, which is marketed directly to healthcare providers and practitioners. This involves an intricate network of sales representatives and a hands-on approach to training medical professionals on the benefits and use of their systems, ensuring that the technology translates efficiently into patient treatment. By focusing extensively on a specific segment within the broader medical device industry, Axonics has positioned itself to capitalize on a substantial market opportunity, driven by an aging population and increasing rates of incontinence-related conditions. This strategic approach not only underscores its commitment to delivering effective healthcare solutions but also signifies its potential for sustained growth within a competitive landscape.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Axonics Inc's most recent financial statements, the company has Operating Margin of -1.7%.
You don't have any saved screeners yet